Monday, January 9, 2012

GSK to seek approval of Theravance lung drug

GlaxoSmithKline will seek approval of the COPD drug Relovair in the United States and Europe in mid-year, and it and partner Theravance Inc. will continue to talk to regulators about also using the drug for asthma patients.
The news initially appears to be a win for South San Francisco-based Theravance (NASDAQ: THRX), which co-developed the drug with GSK, after Astellas Pharma last week returned the antibiotic drug Vibativ to Theravance. But Theravance stock dropped Monday after GSK said it is investigating reports of fatal pneumonia in an undisclosed number of patients on the highest dose of Relovair.
That is not the dosage for which GSK (NYSE: GSK) will seek approval.

No comments:

Post a Comment